Lowering intraglomerular pressure using renin–angiotensin system inhibitors may be a useful therapeutic strategy, and SGLT-2 inhibition may have a broader range of renoprotective effects including reductions in body weight, hyperglycaemia as well as intraglomerular hypertension. The gene discussed is SLC5A2; the disease is Hypertension.